- Home
- NAMS vs TBBK Comparison
NAMS vs TBBK Comparison
Compare NAMS & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- TBBK
- Stock Information
- Founded
- NAMS 2019
- TBBK 1999
- Country
- NAMS Netherlands
- TBBK United States
- Employees
- NAMS N/A
- TBBK N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- TBBK Major Banks
- Sector
- NAMS Health Care
- TBBK Finance
- Exchange
- NAMS Nasdaq
- TBBK Nasdaq
- Market Cap
- NAMS 2.2B
- TBBK 2.4B
- IPO Year
- NAMS N/A
- TBBK 2004
- Fundamental
- Price
- NAMS $18.11
- TBBK $51.10
- Analyst Decision
- NAMS Strong Buy
- TBBK Buy
- Analyst Count
- NAMS 6
- TBBK 3
- Target Price
- NAMS $42.83
- TBBK $67.00
- AVG Volume (30 Days)
- NAMS 694.5K
- TBBK 340.0K
- Earning Date
- NAMS 05-08-2025
- TBBK 07-24-2025
- Dividend Yield
- NAMS N/A
- TBBK N/A
- EPS Growth
- NAMS N/A
- TBBK 20.50
- EPS
- NAMS N/A
- TBBK 4.42
- Revenue
- NAMS $47,140,000.00
- TBBK $502,282,000.00
- Revenue This Year
- NAMS N/A
- TBBK N/A
- Revenue Next Year
- NAMS N/A
- TBBK $6.71
- P/E Ratio
- NAMS N/A
- TBBK $11.57
- Revenue Growth
- NAMS 586.97
- TBBK 10.02
- 52 Week Low
- NAMS $14.06
- TBBK $31.51
- 52 Week High
- NAMS $27.29
- TBBK $65.84
- Technical
- Relative Strength Index (RSI)
- NAMS 47.80
- TBBK 47.93
- Support Level
- NAMS $16.79
- TBBK $50.00
- Resistance Level
- NAMS $19.58
- TBBK $52.84
- Average True Range (ATR)
- NAMS 0.94
- TBBK 1.33
- MACD
- NAMS -0.12
- TBBK -0.32
- Stochastic Oscillator
- NAMS 47.07
- TBBK 20.64
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.